MENS

Jyong Biotech Ltd is a Taiwan-based science-driven biotechnology company. The Company is mainly engaged in developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the United States (U.S.), the European Union (EU), and Asia. The Company has been developing a series of botanical drug candidates, including primary botanical drug candidate of MCS-2, another clinical-stage botanical drug candidate of PCP, and other preclinical-stage botanical drug candidates. MCS-2 is a new botanical drug candidate developed for treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). PCP is a new botanical drug candidate developed for the prevention of prostate cancer.

Wall Street analysts forecast MENS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MENS is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Jyong Biotech Ltd revenue for the last quarter amounts to NaN USD, decreased % YoY.

Jyong Biotech Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

Jyong Biotech Ltd (MENS) has 29 emplpoyees as of December 17 2025.

Today MENS has the market capitalization of 1.17B USD.